Pharmacological treatment of type 2 diabetes mellitus is done by understanding the pathophysiology of the disease and mechanisms of drug action. The oral treatment of type 2 diabetes mellitus currently represents a challenge to physicians, as they face the breakdown of old paradigms, in addition to the technological, marketing and research have increased the current information to which the general practitioners and specialists have no access, such is the case of multiple studies of combined therapy with oral agents in type 2 diabetes mellitus.
In the past decade were conducted multiple intervention studies that showed that intensive glucose control dramatically lowers the risk of micro vascular complications in Type 1 and 2. The aim of these is to maintain the fasting glucose as close to normal and an HbA1c below 7.5%.
The main study intervention is Prospective Diabetes Study UK (UKPDS), which was carried in stages: changes in lifestyle, monotherapy, combination oral and insulin.
The resistance to insulin and beta cell failure of the pancreas are important factors in the development of type 2 diabetes mellitus, also taking into account the role of lipid metabolism in the genesis of hyperglycemia.
The current drugs available to treat based on their mechanism of action: insulin secretagogues, biguanides, ciglitazonas alpha-glucosidase inhibitors. The insulin secretagogues and alpha-glucosidase inhibitors affect postprandial glucose, while the remaining influence
in fasting glucose.
Many studies have reported the usefulness of combination therapy when monotherapy fails, others report double combination, the most common is an insulin secretaryship and insulin sensitize, other studies report sustained in the triple combination of beta cell failure that was reported in the UKPDS study, but there are few studies of any intervention. Combination therapy using insulin fault afternoon Oral plus a single drug as mono therapy.
The use of oral combination translates into advantage and effectiveness for patients in the primary treatment, but physicians should be aware of the side effects as they increase as comorbidities and costs.
Treatment of obesity in patients with type 2 diabetes has now become important, as there are studies in which these drugs are used in combination with an anti hyperglycaemic agent. The following presentations will focus on oral drug combination in the treatment of type 2 diabetes.
Incoming search terms for the article:
pharmacologiacal treatment of type1 diabetes/Tags: combination oral and insulin, monotherapy, Pharmacological Treatment, the development of type 2 diabetes mellitus, treatment of type 2 diabetes mellitus, type 2 diabetes mellitus
